Aspects of pneumococcal infection including bacterial virulence, host response and vaccination

References

1. Abramson N., Alper C. A., Lachmann P. J., Rosen F. S., Jandl J. H. 1971; Deficiency of C3 inactivator in man. Journal of Immunology 107:19–27
   [Google Scholar]
2. Alper C. A., Abramson N., Johnston R. B., Jandl J. H., Rosen F. S. 1970; Studies in vitro and in vivo on an abnormality in the metabolism of C3 in a patient with an increased suscepti bility to infection. Journal of Clinical Investigation 49:1975–1985
   [Google Scholar]
3. Austrian R., Gold J. 1964; Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Annals of Internal Medicine 60:759–776
   [Google Scholar]
4. Austrian R. 1981a; Pneumococcus: The first hundred years. Reviews of Infectious Diseases 3:183–189
   [Google Scholar]
5. Austrian R. 1981b; Some observation on the pneumococcus and on the current status of pneumococcal disease and its prevention. Reviews of Infectious Diseases 3: Suppl S1–S17
   [Google Scholar]
6. Avery O. T., Dubos R. 1931; The protective action of a specific enzyme against type-III pneumococcus infection in mice. Journal of Experimental Medicine 54:73–89
   [Google Scholar]
7. Baker P. J., Stashak P. W. 1969; Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at the cellular level. Journal of Immunology 103:1342–1348
   [Google Scholar]
8. Baker P. J., Amsbaugh D. F., Stashak P. W., Caldes G., Prescott B. 1981; Regulation of the antibody response to the pneumo coccal polysaccharide by thymus-derived cells. Reviews of Infectious Diseases 3:332–341
   [Google Scholar]
9. Barthold D. R., Prescott B., Stashak P. W., Amsbaugh D. F., Baker P. J. 1974; Regulation of the response to type-III pneumococ cal polysaccharide. Ill Role of regulatory T cells in development of an IgG and IgA response. Journal of Immunology 112:1042–1050
   [Google Scholar]
10. Bjornson A. B., Lobel J. S. 1986; Lack of a requirement for the Fc region of the IgG in restoring pneumococcal opsonization via the alternative complement pathway in sickle cell disease. Journal of Infectious Diseases 154:760–769
    [Google Scholar]
11. Bjornson A. B., Lobel J. S., Harr K. S. 1985; Relation between serum opsonic activity for Streptococcus pneumoniae and comple ment function in sickle cell disease. Journal of Infectious Diseases 152:701–709
    [Google Scholar]
12. Braley-Mullen H. 1986a; Requirements for activation of contra-suppressor T cells by type-III pneumococcal polysaccharide. Journal of Immunology 136:396–401
    [Google Scholar]
13. Braley-Mullen H. 1986b; Characterization and activity of contra-suppressor T cells induced by type-III pneumococcal polysaccharide. Journal of Immunology 137:2761–2767
    [Google Scholar]
14. Briles E. B., Tomasz A. 1973; Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid. Journal of Biological Chemistry 248:6394–6397
    [Google Scholar]
15. Briles D. E., Formann D., Hudak S., Claflin J. L. 1984; The effects of idiotype on the ability of IgG, anti-phophorylcholine antibodies to protect mice from fatal infection with Streptococcus pneumoniae. European Journal of Immunology 14:1027–1030
    [Google Scholar]
16. Briles D. E. 1987; Naturally occuring antibodies to phosphocholine as a potential index of antibody responsive ness to polysaccharides. Journal of Infectious Diseases 155:1307–1314
    [Google Scholar]
17. Brown E. J., Joiner K. A., Cole R. M., Berger M. 1983; Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infection and Immunity 39:403–409
    [Google Scholar]
18. Burman L. A., Norrby R., Trollfors B. 1985; Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Reviews of Infectious Diseases 7:133–142
    [Google Scholar]
19. Chetty C., Kreger A. 1985; Generation of purpura-producing principle from pneumococcal cell walls. Journal of Bacteriology 163:389–391
    [Google Scholar]
20. Chudwin D. S., Artrip S. G., Korenblit A., Schiffman G., Rao S. 1985; Correlation of serum opsonins with in-vitro phagocy tosis of Streptococcus pneumoniae. Infection and Immunity 50:213–217
    [Google Scholar]
21. Chudwin D. S., Artrip S. G., Schiffman G. 1987; Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. Clinical Immunology and Immunopathology 44:114–121
    [Google Scholar]
22. Cohn D. A., Schiffman G. 1987; Immunoregulatory role of the spleen in the antibody responses to pneumococcal polysac charide antigens. Infection and Immunity 55:1375–1380
    [Google Scholar]
23. Crews S., Griffin J., Huang H., Calame K., Hood L. 1981; A single VH gene segment encodes the immune response to phosphocholine: somatic mutation is correlated with the class of the antibody. Cell 25:59–66
    [Google Scholar]
24. Dhingra R. K., Williams J. C., Reed W. P. 1977; Effect of pneumococcal mucopeptide and capsular polysaccharide on phagocytosis. Infection and Immunity 15:169–174
    [Google Scholar]
25. Dochez A. R., Avery O. T. 1917; The elaboration of specific soluble substance by pneumococci during growth. Journal of Experimental Medicine 26:477–493
    [Google Scholar]
26. Dowling J. N., Sheehe P. R., Feldman H. A. 1971; Pharyngeal pneumococcal acquisitions in “normal” families: a longi tudinal study. Journal of Infectious Diseases 124:9–17
    [Google Scholar]
27. Ferrante A., Rowan-Kelly B., Paton J. C. 1984; Inhibition of in-vitro human response by the pneumococcal toxin pneumo-lysin. Infection and Immunity 46:585–589
    [Google Scholar]
28. Fine D. P. 1975; Pneumococcal type-associated variability in alternate complement pathway activation. Infection and Immunity 12:772–778
    [Google Scholar]
29. Forrester H. L., Jahnigen D. W., LaForce F. M. 1987; Inefficacy of pneumococcal vaccine in a high-risk population. American Journal of Medicine 83:425–430
    [Google Scholar]
30. Giebink G. S., Le C. T., Schiffman G. 1984; Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides. Journal of Pediat rics 105:576–582
    [Google Scholar]
31. Gransden W. R., Eykyn S. J., Phillips I. 1985; Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas’s Hospital. British Medical Journal 290:505–508
    [Google Scholar]
32. Gray B. M., Dillon H. C., Briles D. E. 1983; Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. Journal of Clinical Microbiology 18:1102–1107
    [Google Scholar]
33. Gruer L. D., McKendrick M. W., Geddes A. M. 1984; Pneumococcal bacteraemia—a continuing challenge. Quarterly Journal of Medicine 53:259–270
    [Google Scholar]
34. Heidelberger M., Jann K., Jann B. 1985; Crossreactions of Escherichia coli K and O polysaccharides in anti-pneumococcal and anti-Salmonella sera. Journal of Experimental Medicine 162:1350–1358
    [Google Scholar]
35. Heidelberger M., Horton D., Haskell T. H. 1986; Cross-reactions of lipopolysaccharides of Pseudomonas aeruginosa in antip neumococcal and other antisera. Infection and Immunity 54:928–930
    [Google Scholar]
36. Heilmann C. 1987; Vaccination-induced activation of human blood T cells supressing pneumococcal polysaccharide-specific B cells. Acta Pathologica Microbiologica et Immunol-ogica Scandinavica(C) 95:65–69
    [Google Scholar]
37. Hendley J. O., Sande M. A., Stewart P. M., Gwaltney J. M. 1975; Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. Journal of Infectious Diseases 132:55–61
    [Google Scholar]
38. Holmberg H., Krook A., Sjogren A. M. 1985; Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia. Journal of Clinical Microbiology 22:808–814
    [Google Scholar]
39. Holtje J. V., Tomasz A. 1975; Specific recognition of choline residues in the cell wall teichoic acid by the N-acetylmura-myl-L-alanine amidase of pneumococcus. Journal of Biological Chemistry 250:6072–6076
    [Google Scholar]
40. Home D., Tomasz A. 1985; Pneumococcal Forssman antigen: enrichment in mesosomal membranes and specific binding to the autolytic enzyme of Streptococcus pneumoniae. Journal of Bacteriology 161:18–24
    [Google Scholar]
41. Hostetter M. K. 1986; Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. Journal of Infectious Diseases 153:682–693
    [Google Scholar]
42. Hummell D. S., Swift A. J., Tomasz A., Winkelstein J. A. 1985; Activation of the alternative complement pathway by pneumococcal lipoteichoic acid. Infection and Immunity 47:384–387
    [Google Scholar]
43. Jennings H. J., Lugowski C., Young N. M. 1980; Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type I. Biochemistry 19:4712–4719
    [Google Scholar]
44. Joiner K., Brown E., Hammer C., Warren K., Frank M. 1983; Studies on the mechanism of bacterial resistance to complement-medicated killing III C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing. Journal of Immunology 130:845–849
    [Google Scholar]
45. Jonsson S., Musher D. M., Chapman A., Goree A., Lawrence E. C. 1985; Phagocytosis and killing of common bacterial patho gens of the lung by human alveolar macrophages. Journal of Infectious Diseases 152:4–13
    [Google Scholar]
46. Kaplan J., Samaik S., Schiffman G. 1986; Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia. American Journal of Pediatric Hematology and Oncology 8:80–82
    [Google Scholar]
47. Knox K. W., Wicken A. J. 1973; Immunological properties of teichoic acids. Bacteriological Reviews 37:215–257
    [Google Scholar]
48. Lancet (leading article) 1988; Acute respiratory infections in under-fives: 15 million deaths a year. Lancet 2:699–701
    [Google Scholar]
49. Leinonen M., Sakkinen A., Kalliokoski R., Luotonen J., Timonen M., Makela P. H. 1986; Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre school age children. Pediatric Infectious Diseases 5:39–44
    [Google Scholar]
50. Lock R. A., Paton J. C., Hansman D. 1988; Purification and immunological characterization of neuraminidase pro-duced by Streptococcus pneumoniae. Microbial Pathogenesis 4:33–43
    [Google Scholar]
51. MacLeod C. M., Hodges R. G., Heidelberger M., Bernherd W. G. 1945; Prevention of pneumococcal pneumonia by immuni sation with specific capsular polysaccharides. Journal of Experimental Medicine 82:445–465
    [Google Scholar]
52. MacFarlane J. T., Finch R. G., Ward M. J., Macrae A. D. 1982; Hospital study of adult community-acquired pneumonia. Lancet 2:255–258
    [Google Scholar]
53. McDaniel L. S., Benjamin W. H., Forman C., Briles D. E. 1984; Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. Journal of Immunology 133:3308–3312
    [Google Scholar]
54. McDaniel L. S., Yother J., Vijayakumar M., McGarry L., Guild W. R., Briles D. E. 1987; Use of insertional inactivation to facilitate studies of biological properties of pneumoncoccal surface protein A (PspA). Journal of Experimental Medicine 165:381–394
    [Google Scholar]
55. Mold C., Edwards K. M., Gewurz H. 1982a; Effect of C-reactive protein on the complement-mediated stimulation of human neutrophils by Streptococcus pneumoniae serotypes 3 and 6. Infection and Immunity 37:987–992
    [Google Scholar]
56. Mold C., Rodgers C. P., Kaplan R. L., Gewurz H. 1982b; Binding of C-reactive protein to bacteria. Infection and Immunity 38:392–395
    [Google Scholar]
57. Morbidity and Mortality Weekly Report 1981; 30:33410
58. Mufson M. A., Krausa H. E., Schiffman G., Hughey D. F. 1987; Pneumococcal antibody levels one decade after immuniza tion of healthy adults. American Journal of Medical Science 293:279–284
    [Google Scholar]
59. Mufson M. A., Kruss D. M., Wasil R. E., Metzger W. I. 1974; Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Archives of Internal Medicine 134:505–509
    [Google Scholar]
60. Musher D. M., Chapman A. J., Goree A., Jonsson S., Briles D., Baughn R. E. 1986; Natural and vaccine-related immunity to Streptococcus pneumoniae. Journal of Infectious Diseases 154:245–256
    [Google Scholar]
61. Nandoskar M., Ferrante A., Bates E. J., Hurst N., Paton J. C. 1986; Inhibition of human monocyte respiratory burst, degranu lation, phospholipid methylation and bacteriocidal activity by pneumolysin. Immunology 59:515–520
    [Google Scholar]
62. Newman S. L., Vogler L. B., Feigin R. D., Johnston R. B. 1978; Recurrent septicemia associated with congenital deficiency of C2 and a partial deficiency of factor B and the alternative complement pathway. New England Journal of Medicine 299:290–292
    [Google Scholar]
63. Pasanen V. J., Asofsky T., Baker P. J. 1979; Synthesis of two classes of antibody IyM and IyG or IyM and IyA by identical cells: amplification of the antibody response to pneumococcal polysaccharide type III. Journal of Experi mental Medicine 149:1227–1237
    [Google Scholar]
64. Paton J. C., Ferrante A. 1983; Inhibition of human polymorphonuclear leukocyte respiratory burst, bacteriocidal activity and migration by pneumolysin. Infection and Immunity 41:1212–1216
    [Google Scholar]
65. Paton J. C., Lock R. A., Hansman D. J. 1983; Effect of immunization with pneumolysin of survival time in mice challenged with Streptococcus pneumoniae. Infection and Immunity 40:548–552
    [Google Scholar]
66. Paton J. C., Rowam-Kelly B., Ferrante A. 1984; Activation of human complement by the pneumococcal toxin pneumoly sin. Infection and Immunity 43:1085–1087
    [Google Scholar]
67. Pepys J., Longbottom J. L. 1971; Antigenic and C-substance activities of related glycopeptides from fungal, parasitic and vegetable sources. International Archives of Allergy and Applied Immunology 41:219–221
    [Google Scholar]
68. Plotkowski M. C., Puchelle E., Beck G., Jacquot J., Hannoun C. 1986; Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. American Review of Respiratory Diseases 134:1040–1044
    [Google Scholar]
69. Porro M., Costantino P., Viti S., Vannozzi F., Naggi A., Torri G. 1985; Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glyconconjugate antigen. Molecular Immunology 22:907–919
    [Google Scholar]
70. Pritchard D. G., Volanakis J. E., Slutsky G. M., Greenblatt C. L. 1985; C-Reacti ve protein binds leishmanial excreted factors. Proceedings of the Society for Experimental Biology and Medicine 178:500–503
    [Google Scholar]
71. Reed W. P., Davidson M. S., Williams R. C. 1976; Complement system in pneumococcal infections. Infection and Immunity 13:1120–1125
    [Google Scholar]
72. Riley I. D., Douglas R. M. 1981; An epidemiologic approach to pneumococcal disease. Reviews of Infectious Diseases 3:233–245
    [Google Scholar]
73. Riley I. D., Lehmann D., Alpers M. P., Marshall T. F., de C., Gratten H., Smith D. 1986; pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean Children. Lancet 2:877–881
    [Google Scholar]
74. Robbins J. B. 1983; Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. Journal of Infectious Diseases 148:1136–1159
    [Google Scholar]
75. Rynnel-Dagoo B., Freijd A., Hammarstrom L., Oxelius V., Persson M. A., Smith C. 1986; Pneumococcal antibodies of different immunoglobulin subclasses in normal and IgG subclass deficient individuals of various ages. Acta Otolaryngologica 101:146–151
    [Google Scholar]
76. Schwartz J. S. 1982; Pneumococcal vaccine: clinical efficacy and effectiveness. Annals of Internal Medicine 96:208–220
    [Google Scholar]
77. Schulkind M. L., Ellis E. F., Smith R. T. 1967; Effect of antibody on the clearance of¹²⁵ T labelled pneumococci by the spleen and liver. Pediatric Research 1:178–184
    [Google Scholar]
78. Schweinle J. E. 1986; Pneumococcal intracellular killing is abolished by polysaccharides despite serum complement activity. Infection and Immunity 54:876–881
    [Google Scholar]
79. Simberkoff M. S. 1986; Efficacy of pneumococcal vaccine in high-risk patients. Results of a veterans administration cooperative study. New England Journal of Medicine 315:1318–1327
    [Google Scholar]
80. Sims R. V., Steinmann W. C., McConville J. H., King L. R., Zwick W. C., Schwartz J. S. 1988; The clinical effectiveness of pneumococcal vaccination in the elderly. Annals of Internal Medicine 108:653–657
    [Google Scholar]
81. Sugane K., Oshima T. 1983; Activation of complement in C-reactive protein positive sera by phosphorylcholine-bearing component isolated from parasite extract. Parasite Immunology 5:385–395
    [Google Scholar]
82. Tilghman R. C., Finland M. 1937; Clinical significance of bacteremia in pneumococcic pneumonia. Archives of Internal Medicine 59:602–619
    [Google Scholar]
83. Tillet W. S. 1928; Active and passive immunity to pneumococcus infection induced in rabbits by immunization with pneu mococci. Journal of Experimental Medicine 48:791–804
    [Google Scholar]
84. Vered M., Dearing R., Janoff A. 1985; A new elastase inhibitor from Streptococcus pneumoniae protects against acute lung injury induced by neutrophil granules. American Review of Respiratory Disease 131:131–133
    [Google Scholar]
85. Vered M., Schutzbank T., Janoff A. 1984; Inhibitors of human neutrophil elastase in extracts of Streptococcus pneumoniae. American Reviews of Respiratory Disease 130:1118–1124
    [Google Scholar]
86. Vial W. C., Toews G. B., Pierce A. K. 1984; Early pulmonary granulocyte recruitment in response to Streptococcus pneumoniae. American Review of Respiratory Disease 129:87–91
    [Google Scholar]
87. Walker J. A., Allen R. L., Falmagne P., Johnson M. K., Boulnois G. J. 1987; Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infection and Immunity 55:1184–1189
    [Google Scholar]
88. Wallick S., Claflin J. L., Briles D. E. 1983; Resistance to Streptococcus pneumonia is induced by a phosphocholine-protein conjugate. Journal of Immunology 130:2871–2875
    [Google Scholar]
89. Wara D. W. 1981; Host defense against Streptococcus pneumoniae: the role of the spleen. Reviews of Infectious Diseases 3:299–309
    [Google Scholar]
90. Ward M. M., Ward R. E., Huang J.-H., Kohler H. 1987; Idiotype vaccine against Streptococcus pneumoniae. A precursor study. Journal of Immunology 139:2775–2780
    [Google Scholar]
91. White B. 1938; The biology of the pneumococcus; the bacteriolog ical, biochemical and immunological character and active ties of Diplococcus pneumoniae. The Commonwealth Fund; New York:
    [Google Scholar]
92. Winkelstein J. A. 1981; The role of complement in the host’s defense against Streptococcus pneumoniae. Reviews of Infectious Diseases 3:289–298
    [Google Scholar]
93. Winkelstein J. A., Tomasz A. 1978; Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. Journal of Immunology 120:174–178
    [Google Scholar]
94. Winkelstein J. A., Smith M. R., Slim H. S. 1975; The role of C3 as an opsonin the early stages of infection. Proceedings of the Society for Experimental Biology and Medicine 149:397–401
    [Google Scholar]
95. Woodhead M. A., MacFarlane J. T., Rodgers F. G., Laverick A., Pilkington R., Macrae A. D. 1985; Aetiology and outcome of severe community-acquired pneumonia. Journal of Infection 10:204–210
    [Google Scholar]
96. Yother J., Volanakis J. E., Briles D. E. 1982; Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. Journal of Immunology 128:2374–2376
    [Google Scholar]